Removal of the receptor increased amyloid pathology, indicating that M1 mAChR is instrumental in modulating amyloidogenic APP processing in neurons with M1 activators as potential therapeutic resources for treating AD [134]. This evidence concerns the gene APP and Alzheimer disease.